Biopharmaceutical company, Intra-Cellular Therapies, has announced U.S. Food and Drug Administration (FDA) approval of CAPLYTA to treat bipolar I and bipolar II disorders. Bipolar is a mental disorder characterized by unusual mood swings, energy levels, and concentration, typically expressed through manic and depressive episodes, affecting around 11 million U.S. adults. The drug, CAPLYTA, is an antipsychotic treatment that modulates levels of dopamine, serotonin, and glutamate, neurotransmitters associated with bipolar and schizophrenia conditions. Currently, there is a lack of antidepressant monotherapies for bipolar depression on the market and antidepressants are typically prescribed in combination with an antimanic agent to regulate the varying mood swings commonly expressed in bipolar I and II disorders. Intra-Cellular Therapies researches and develops innovative small-molecule drugs to treat people living with complex neurological and psychiatric diseases.
Read more here.